Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
8.26
+0.21 (2.61%)
Oct 29, 2024, 4:00 PM EDT - Market closed

Company Description

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.

The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.

The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.

In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder.

The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA.

The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023.

Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Zevra Therapeutics, Inc.
Zevra Therapeutics logo
Country United States
Founded 2006
IPO Date Apr 16, 2015
Industry Biotechnology
Sector Healthcare
Employees 69
CEO Neil McFarlane

Contact Details

Address:
1180 Celebration Boulevard, Suite 103
Celebration, Florida 34747
United States
Phone 321 939 3416
Website zevra.com

Stock Details

Ticker Symbol ZVRA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001434647
ISIN Number US4884452065
Employer ID 20-5894398
SIC Code 2834

Key Executives

Name Position
Neil F. McFarlane President, Chief Executive Officer and Director
Christal M. M. Mickle M.A. Co-Founder and Chief Development Officer
R. LaDuane Clifton CPA Chief Financial Officer, Secretary and Treasurer
Joshua M. Schafer M.B.A. Chief Commercial Officer and Executive Vice President of Business Development
Dr. Sven Guenther Ph.D. Chief Scientific Officer
Nichol L. Ochsner Vice President of Investor Relations and Corporate Communications
Rahsaan W. Thompson J.D. Chief Legal Officer, Secretary and Compliance Officer
Alison Peters Chief People Officer
Dr. Christopher M. Lauderback Ph.D. Senior Vice President of Manufacturing
Dr. Rene A. Braeckman Ph.D. Senior Vice President of Clinical Development

Latest SEC Filings

Date Type Title
Sep 20, 2024 8-K Current Report
Aug 14, 2024 10-Q Quarterly Report
Aug 13, 2024 8-K Current Report
Aug 9, 2024 8-K Current Report
Aug 9, 2024 424B5 Filing
Aug 8, 2024 8-K Current Report
Aug 8, 2024 424B5 Filing
Aug 5, 2024 8-K Current Report
Jul 12, 2024 8-K Current Report
Jul 12, 2024 424B2 Prospectus